MedTrace Logo

Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT07719621 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50000

Last updated 2026-08-19

No results posted yet for this study

Summary

The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes mellitus.

The main questions it aims to answer are:

* How many events of heart failure, heart failure hospitalizations, and cardiovascular death happen in each group?
* How do serious kidney problems progress in each of the groups?

Researchers will compare reference therapy (finerenone) with a combination of finerenone and empagliflozin.

There will not be human participants in this study. With the help of artificial intelligence, researchers will recreate a large population of people with chronic kidney disease and type 2 diabetes mellitus. Data on their disease, treatment, and laboratory parameters will be based on and simulated using real data from previous clinical trials conducted with real participants.

Conditions

  • CKD - Chronic Kidney Disease
  • Diabetes Mellitus Type 2

Sponsors & Collaborators

  • Bayer Hispania, S.L

    collaborator UNKNOWN

  • Aeterna Medical Solutions SL

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2026-11-30
Completion
2026-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07719621 on ClinicalTrials.gov